Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Spero Therapeutics, Inc. - Common Stock
(NQ:
SPRO
)
2.500
+0.370 (+17.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Spero Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Earnings Outlook For Spero Therapeutics
March 12, 2024
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 04, 2023
Via
Benzinga
Recap: Spero Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
Earnings Outlook For Spero Therapeutics
November 10, 2023
Via
Benzinga
4 Analysts Have This to Say About Spero Therapeutics
September 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 13, 2023
Via
Benzinga
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 02, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Overview Of Value Stocks In The Healthcare Sector
September 18, 2023
Via
Benzinga
Spero Therapeutics's Earnings: A Preview
August 09, 2023
Via
Benzinga
Recap: Spero Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
Spero Therapeutics's Earnings Outlook
May 10, 2023
Via
Benzinga
Spero Therapeutics's Earnings: A Preview
March 29, 2023
Via
Benzinga
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Earnings Outlook For Spero Therapeutics
March 10, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know
August 14, 2023
Via
Benzinga
Earnings Scheduled For May 11, 2023
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
March 31, 2023
It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday!
Via
InvestorPlace
Earnings Scheduled For March 30, 2023
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Earnings Outlook For Spero Therapeutics
November 11, 2022
Spero Therapeutics (NASDAQ:SPRO) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that Spero...
Via
Benzinga
Earnings Scheduled For November 14, 2022
November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Via
Benzinga
How Is The Market Feeling About Spero Therapeutics?
October 10, 2022
Spero Therapeutics's (NASDAQ:SPRO) short percent of float has risen 180.65% since its last report. The company recently reported that it has 777 thousand shares sold short, which is 2.61% of all...
Via
Benzinga
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
October 04, 2022
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Via
Benzinga
This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike
September 26, 2022
UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.
Via
Benzinga
Short Volatility Alert: Spero Therapeutics, Inc.
September 23, 2022
On Thursday, shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) experienced volatile short activity. After the activity, the stock price went up +168.29% to $2.20. The overall sentiment for SPRO has...
Via
Benzinga
Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
September 23, 2022
Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero...
Via
Benzinga
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
September 23, 2022
Gainers
Via
Benzinga
Dow Turns Higher; Crude Oil Rises 0.7%
September 22, 2022
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.